"Missing mutations" in MPS I: Identification of two novel copy number variations by an IDUA-specific in house MLPA assay.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
09 2019
Historique:
received: 14 12 2018
revised: 06 02 2019
accepted: 11 02 2019
pubmed: 19 7 2019
medline: 18 6 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Mucopolysaccharidosis type I (MPS I) is a rare, recessively inherited lysosomal storage disorder, characterized by progressive multi-systemic disease. It is caused by a reduced or absent alpha-l iduronidase (IDUA) enzyme activity secondary to biallelic loss-of-function variants in the IDUA. Over 200 causative variants in IDUA have been identified. Nevertheless, there is a fraction of MPS I patients with only a single mutated IDUA allele detectable. As genetic testing of MPS I is usually based on sequencing methods, copy number variations (CNVs) in IDUA can be missed and therefore presumably remain underdiagnosed. The aim of this study was the detection of CNVs using an IDUA-specific in house multiplex ligation-dependent probe amplification (MLPA) assay. A total of five unrelated MPS I patient samples were re-analyzed after only a single heterozygous IDUA mutation c.979G>C (p.A327P), c.1469T>C (p.L490P), c.1598C>G (p.P533R), c.1205G>A (p.W402X), c.973-7C>G (p.?) could be identified. We detected a novel splice site variant c.973-7C>G (p.?), as well as two novel CNVs, a large deletion of IDUA exon 14 and 3'UTR c.(1828 + 1_1829-1)_(*1963_?)del, and a large duplication extending from IDUA exon 2 to intron 12 c.(157 + 1_158-1)_(1727 + 1_1728-1)dup. Together with the CNVs we previously identified, a total of four pathogenic IDUA CNVs have now been reported.

Sections du résumé

BACKGROUND
Mucopolysaccharidosis type I (MPS I) is a rare, recessively inherited lysosomal storage disorder, characterized by progressive multi-systemic disease. It is caused by a reduced or absent alpha-l iduronidase (IDUA) enzyme activity secondary to biallelic loss-of-function variants in the IDUA. Over 200 causative variants in IDUA have been identified. Nevertheless, there is a fraction of MPS I patients with only a single mutated IDUA allele detectable.
METHODS
As genetic testing of MPS I is usually based on sequencing methods, copy number variations (CNVs) in IDUA can be missed and therefore presumably remain underdiagnosed. The aim of this study was the detection of CNVs using an IDUA-specific in house multiplex ligation-dependent probe amplification (MLPA) assay.
RESULTS
A total of five unrelated MPS I patient samples were re-analyzed after only a single heterozygous IDUA mutation c.979G>C (p.A327P), c.1469T>C (p.L490P), c.1598C>G (p.P533R), c.1205G>A (p.W402X), c.973-7C>G (p.?) could be identified. We detected a novel splice site variant c.973-7C>G (p.?), as well as two novel CNVs, a large deletion of IDUA exon 14 and 3'UTR c.(1828 + 1_1829-1)_(*1963_?)del, and a large duplication extending from IDUA exon 2 to intron 12 c.(157 + 1_158-1)_(1727 + 1_1728-1)dup.
CONCLUSION
Together with the CNVs we previously identified, a total of four pathogenic IDUA CNVs have now been reported.

Identifiants

pubmed: 31319022
doi: 10.1002/mgg3.615
pmc: PMC6732313
doi:

Substances chimiques

IDUA protein, human EC 3.2.1.76
Iduronidase EC 3.2.1.76

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00615

Informations de copyright

© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Références

Hum Mutat. 1992;1(2):103-8
pubmed: 1301196
Trends Biochem Sci. 1998 Jun;23(6):198-9
pubmed: 9644970
Acta Paediatr. 1995 Mar;84(3):337-9
pubmed: 7780260
Am J Hum Genet. 1993 Nov;53(5):973-86
pubmed: 8213840
Biochim Biophys Acta. 1998 Sep 30;1407(3):249-56
pubmed: 9748610
Mol Genet Genomic Med. 2019 Sep;7(9):e00615
pubmed: 31319022
Hum Mutat. 2017 Nov;38(11):1555-1568
pubmed: 28752568
Hum Mol Genet. 1994 Jun;3(6):861-6
pubmed: 7951228
Clin Genet. 2018 Jul;94(1):95-102
pubmed: 29393969
Hum Mutat. 2016 Jul;37(7):703-9
pubmed: 27071356
Clin Genet. 2016 Dec;90(6):496-508
pubmed: 27146977
Hum Mutat. 1992;1(4):333-9
pubmed: 1301941
Hum Genet. 2001 Nov;109(5):503-11
pubmed: 11735025
Hum Genome Var. 2016 Oct 06;3:16031
pubmed: 27766162
Am J Hum Genet. 1990 Nov;47(5):802-7
pubmed: 2220820
Am J Med Genet A. 2009 May;149A(5):965-74
pubmed: 19396826
Hum Mutat. 1995;6(4):288-302
pubmed: 8680403
Hum Genomics. 2011 May;5(4):241-64
pubmed: 21712188
Am J Hum Genet. 2016 Apr 7;98(4):597-614
pubmed: 27040688
Hum Mutat. 2011 Jun;32(6):E2189-210
pubmed: 21394825
Hum Mutat. 1995;6(1):55-9
pubmed: 7550232
Genet Med. 2014 Oct;16(10):759-65
pubmed: 24675674

Auteurs

Amir Jahic (A)

Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany.
Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Sven Günther (S)

Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany.

Nicole Muschol (N)

Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Barbro Fossøy Stadheim (B)

Department of Clinical Genetics, Oslo University Hospital, Oslo, Norway.

Øivind Braaten (Ø)

Department of Clinical Genetics, Oslo University Hospital, Oslo, Norway.

Hanne Kjensli Hyldebrandt (H)

Department of Clinical Genetics, Oslo University Hospital, Oslo, Norway.

Gé-Ann Kuiper (GA)

Pediatric Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Academic Medical Center (AMC), Amsterdam, Netherlands.

Karen Tylee (K)

Manchester Center for Genomic Medicine, St Mary's Hospital, Manchester, UK.

Frits A Wijburg (FA)

Pediatric Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Academic Medical Center (AMC), Amsterdam, Netherlands.

Christian Beetz (C)

Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany.
Centogene AG, Rostock, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH